Boston Scientific is no longer seeking regulatory approval of ACURATE neo2™ or ACURATE Prime™ in the United States or other countries. This decision was made due to the increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.
Patients who have been treated with an ACURATE neo2 valve or ACURATE Prime XL valve as part of the ACURATE IDE clinical trial should continue with their study follow-up care.
For Investigators that would like more information, please contact the Boston Scientific ACURATE IDE study team.
Open stabilization arches
For unrestricted coronary access1 aided by predictable commissure alignment2
Supra-annular leaflets
Designed to provide large EOAs and low gradients3
Connected cells
Designed to allow for equally distributed radial force over circumference*
Active PVseal™ technology
360° dynamic sealing skirt to mitigate PVL4
| Valve Size | 23 mm | 25 mm | 27 mm | 29 mm |
| Aortic annulus diameter** | 20.5 mm - 23 mm | 22.5 mm - 25 mm | 24.5 mm - 27 mm | 26.5 mm - 29 mm |
| Aortic annulus perimeter | 64 mm - 72 mm | 71 mm - 79 mm | 77 mm - 85 mm | 83 mm - 91 mm |